Kura Oncology Reports First Quarter 2026 Financial Results

About this update from Kura Oncology, Inc.

– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase 3 results – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported first quarter 2026 financial results and provided a corporate update. “In its first full quarter of commercial availability, KOMZIFTI generated $5.8 million in net revenue, with early launch dynamics indicating growing physician adoption and utilization patterns based on product profile. We believe these early signals support KOMZIFTI’s potential to become the leading therapy in relapsed/refractory NPM1-mutant AML,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “Supported by a robust clinical development program designed to establish it as a broadly combinable backbone across the AML treatment continuum, and with multiple data readouts expected this year across frontline and combination settings, we are well positioned for the next phase of growth.” Recent Developments KOMZIFTI Launch Performance (First Quarter 2026) KOMZIFTI delivered a strong first full quarter of commercial performance, with early indicators supporting adoption and continued momentum: Early market dynamics, including repeat prescribing, expanding use across treatment settings, initial combination use and instances of switching from other menin inhibitors, indicate growing physician adoption based on product profile. Advancing Ziftomenib Across the Acute Myeloid Leukemia (AML) Treatment Continuum Kura continues to execute on its strategy to establish ziftomenib as a broadly combinable backbone therapy across AM...

View stock analysis, news, and events for Kura Oncology, Inc.